Phio Pharmaceuticals Corp.
Business
Phio Pharmaceuticals Corp. is a clinical-stage biopharmaceutical company developing cancer immunotherapies using its proprietary INTASYL small interfering RNA gene-silencing technology. The company's lead candidate PH-762 targets PD-1 to enhance T-cell killing of tumor cells and is in Phase 1b trials for cutaneous squamous cell carcinoma, melanoma and Merkel cell carcinoma via intratumoral injection. Pipeline compounds target immune checkpoints and tumor microenvironment proteins designed to work without specialized delivery systems, with preclinical synergy data in combination with antibodies and adoptive cell therapies. The company relies on contract manufacturers and operates as a single reportable segment.
Summary from 10-K filed 2026-03-05
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Research and development | 5 | 4 | 6 | 7 | 9 | |
| General and administrative | 5 | 4 | 4 | 4 | 5 | |
| Total operating expenses | 9 | 7 | 11 | 11 | 14 | |
| Operating loss | −9 | −7 | −11 | −11 | −14 | |
| Interest income, net | 520,000 | 231,000 | — | — | — | |
| Other income, net | 2,000 | 6,000 | — | — | — | |
| Net loss | −9 | −7 | −11 | −11 | −13 | |
| Basic and diluted (in dollars per share) | −1.45 | −9.08 | −46.76 | −10.1 | −12.43 | |
| Basic and diluted (in shares) | 6 | 787,466 | 231,508 | 1 | 1 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 21 | 5 | 8 | — | — | |
| Prepaid expenses and other current assets | 445,000 | 354,000 | 832,000 | 615,000 | 620,000 | |
| Total current assets | 21 | 6 | 9 | 12 | 25 | |
| Property and equipment, net | 11,000 | 2,000 | 6,000 | 183,000 | 133,000 | |
| Total assets | 21 | 6 | 9 | 13 | 25 | |
| Accounts payable | 435,000 | 253,000 | 657,000 | 779,000 | 283,000 | |
| Accrued expenses | 905,000 | 762,000 | 942,000 | 1 | 3 | |
| Total liabilities | 1 | 1 | 2 | 2 | 3 | |
| Commitments and contingencies | — | — | — | — | — | |
| Series D Preferred stock, $0.0001 par value, 10,000,000 shares authorized; 0 issued and outstanding at each of December 31, 2025 and December 31, 2024 | 0 | 0 | — | — | 0 | |
| Common stock, $0.0001 par value, 100,000,000 shares authorized; 11,617,250 and 1,733,717 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively | 1,000 | 0 | 0 | 0 | 0 | |
| Additional paid-in capital | 175 | 151 | 147 | 139 | 139 | |
| Accumulated deficit | −155 | −146 | −139 | −128 | −117 | |
| Total stockholders' equity | 20 | 5 | 8 | 11 | 22 | |
| Total liabilities and stockholders' equity | 21 | 6 | 9 | 13 | 25 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Depreciation and amortization | 3,000 | 2,000 | 56,000 | 71,000 | 75,000 | |
| Amortization of right of use asset | 0 | 33,000 | 128,000 | 122,000 | 117,000 | |
| Net gain/(loss) on disposal of property and equipment | 0 | −6,000 | — | — | — | |
| Stock-based compensation | 481,000 | 147,000 | 303,000 | 414,000 | 480,000 | |
| Prepaid expenses and other assets | −91,000 | 481,000 | −196,000 | 8,000 | 241,000 | |
| Accounts payable | 183,000 | −404,000 | −122,000 | 496,000 | −445,000 | |
| Accrued expenses | 143,000 | −180,000 | −83,000 | −2 | 1 | |
| Lease liability | 0 | −35,000 | −135,000 | −125,000 | −116,000 | |
| Net cash (used in) operating activities | −8 | −7 | −11 | −12 | −12 | |
| Cash paid for purchase of property and equipment | −12,000 | −1,000 | −5,000 | −121,000 | −51,000 | |
| Asset sale proceeds | 0 | 9,000 | — | — | — | |
| Net cash (used in) provided by investing activities | −12,000 | 8,000 | −5,000 | −121,000 | −51,000 | |
| Net proceeds from the exercise of warrants | 6 | 4 | — | 0 | 2 | |
| Net proceeds from the issuance of common stock and warrants | 18 | 0 | — | — | — | |
| Cash-in-lieu of fractional shares from reverse stock split | 0 | −1,000 | — | — | — | |
| Payments to repurchase shares withheld for payroll taxes from restricted stock issuance | −30,000 | −5,000 | −26,000 | −28,000 | −1,000 | |
| Net cash provided by financing activities | 24 | 4 | 7 | −26,000 | 22 | |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 16 | −3 | — | — | — | |
| Interest paid | 0 | 13,000 | 11,000 | — | 8,000 |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Phio Pharmaceuticals Corp.'s CIK number?
Phio Pharmaceuticals Corp.'s SEC CIK number is 0001533040 (1533040). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Phio Pharmaceuticals Corp.'s SEC filings?
All of Phio Pharmaceuticals Corp.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did Phio Pharmaceuticals Corp. last report earnings?
Phio Pharmaceuticals Corp. (PHIO) most recently filed an earnings 8-K with the SEC on May 7, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001437749-26-015590). This is Phio Pharmaceuticals Corp.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is Phio Pharmaceuticals Corp.'s most recent earnings 8-K?
Phio Pharmaceuticals Corp.'s latest earnings 8-K (Item 2.02) was filed May 7, 2026 under accession 0001437749-26-015590. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View Phio Pharmaceuticals Corp.'s latest earnings 8-K →
Look up any company's CIK number →